Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

The FDA has granted accelerated approval to zanidatamab for pretreated, advanced HER2-positive biliary tract cancer.

FDA Approves Zanidatamab for Previously Treated, Unresectable or Metastatic HER2+ Biliary Tract Cancer

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.

Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation

An NDA for lisaftoclax in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma has been accepted for review. 

Lisaftoclax NDA Accepted for Review in China for Relapsed/Refractory CLL/SLL

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

David R. Oveisi, MD, discusses how the expanded indications for ide-cel and cilta-cel are affecting treatment decision-making in multiple myeloma.

Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care

The podcast section includes OncLive on Air® podcast episodes, which focus on clinical oncology news and expert insights in cancer care. Listen on OncLive.

Podcasts | Clinical Oncology News & Insights | OncLive

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life’s experiences.

In this episode, Dr Camidge sits down with Rahul Gosain, MD, MBA, the medical director of Wilmot Cancer Institute at Webster and director of Wilmot Cancer Institute Regional Infusion services, as well as an assistant professor of clinical medicine in the Department of Medicine, Hematology/Oncology at the University of Rochester in New York. He is also co-host of the podcast 

Drs Camidge and Gosain discuss how Dr Gosain’s journey through medical school led him to his role as a community oncologist, the challenges he encountered during his early career that inspired him to fill a need for concise yet comprehensive educational resources, and how he harnessed social media and leveraged professional connections to create a podcast highlighting practice updates for up-and-coming oncology professionals.

Drs Camidge and Gosain discuss how Dr Gosain harnessed social media to create a podcast with practice updates for up-and-coming oncology professionals.

How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by PDS Biotech, we had the pleasure of speaking with Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB, about the role of PDS0101 (Versamune HPV) in patients with human papillomavirus type 16 (HPV16)–positive head and neck squamous cell carcinoma (HNSCC). Dr Harrington is head of the Division of Radiotherapy and Imaging at The Institute of Cancer Research in London, United Kingdom, as well as a fellow of the Royal College of Physicians and the Royal College of Radiologists.

In our exclusive interview, Dr Harrington discussed current unmet needs for patients with recurrent/metastatic HNSCC, the rationale for the continued investigation of PDS0101 plus pembrolizumab (Keytruda) in patients with HPV16-positive HNSCC, and how the ongoing phase 3 VERSATILE-003 trial may change the treatment paradigm for patients with this disease. 

That’s all we have for today! Thank you for listening to this episode of 

, supported by PDS Biotech. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

 is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Dr Harrington discusses PDS0101 plus pembrolizumab in HPV16+ HNSCC and how the VERSATILE-003 trial may change the HNSCC treatment paradigm.

HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB

In today’s episode, supported by Astellas Pharma, we had the pleasure of speaking with Jaffer A. Ajani, MD, about the FDA approval of zolbetuximab-clzb (Vylov) plus chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin 18.2 (CLDN18.2) positive. Dr Ajani is a GI medical oncologist and professor in the Department of Gastrointestinal (GI) Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.

On October 18, 2024, the FDA approved zolbetuximab plus fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative, CLDN18.2-positive gastric or GEJ adenocarcinoma. This regulatory decision was backed by findings from the phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) trials. In SPOTLIGHT, In SPOTLIGHT, patients who received zolbetuximab plus mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin) achieved a median progression-free survival (PFS) of 10.6 months (95% CI, 8.9-12.5) vs 8.7 months (95% CI, 8.2-10.3) in those who received placebo plus chemotherapy (HR, 0.750; 95% CI, 0.601-0.936; 1-sided 

 = .0053). In GLOW, zolbetuximab plus CAPOX (capecitabine and oxaliplatin) generated a median PFS of 8.2 months (95% CI, 7.5-8.8) vs 6.8 months (95% CI, 6.1-8.1) with placebo plus CAPOX (HR, 0.771; 95% CI, 0.615-0.965; 1-sided 

In our exclusive interview, Dr Ajani discussed key considerations for the clinical use of zolbetuximab, including its anticipated adverse effect profile and the introduction of CLDN18.2 as a biomarker for assessment prior to treatment initiation.

, supported by Astellas Pharma. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

Dr Ajani discusses the FDA approval of frontline zolbetuximab plus chemo for unresectable or metastatic, HER2–, CLDN18.2+ gastric or GEJ adenocarcinoma. 

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

In this episode, Dr Camidge sits down with Duncan McLaren, MBBS, BSc, FRCR, FRCP, a consultant clinical oncologist at Spire Edinburgh Hospitals Murrayfield and Shawfair Park, as well as a professor at the Edinburgh Cancer Research Centre at The University of Edinburgh in Scotland.

Drs Camidge and McLaren discuss Dr McLaren’s unconventional journey to medical school, his experience as a clinical oncologist with expertise across oncology disciplines, and how his clinical research focus works to change the course of radiation therapy for genitourinary cancers.

Drs Camidge and McLaren discuss Dr McLaren’s journey to medical school and his experience as a clinical oncologist with expertise across disciplines.

Clinical Oncology Bridges Gaps Between Medical Oncology, Radiation Oncology, and Clinical Research: With D. Ross Camidge, MD, PhD; and Duncan McLaren, MBBS, BSc, FRCR, FRCP

In today’s episode, supported by Corcept Therapeutics, we had the pleasure of speaking with Premal Thaker, MD, MS, about the use of the selective glucocorticoid receptor modulator relacorilant (CORT125134) in patients with ovarian cancer. Dr Thaker is the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology, as well as the director of Gynecologic Oncology Clinical Research and the interim chief of the Division of Gynecologic Oncology at the School of Medicine at the Washington University in St. Louis and the Siteman Cancer Center in Missouri.

In our exclusive interview, Dr Thaker discussed the rationale for combining relacorilant with nab-paclitaxel (Abraxane) in patients with platinum-resistant ovarian cancer, striking phase 2 data (NCT03776812) with this combination in this population, and what the future has in store regarding the phase 3 ROSELLA trial (NCT05257408).

, supported by Corcept Therapeutics. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

Dr Thaker discusses the rationale for combining relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer, and the future of the ROSELLA trial.

Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS

®! I’m your host today, Ashling Wahner.

®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

In today’s episode, supported by AstraZeneca, we had the pleasure of speaking with Kevin Kalinsky, MD, MS, about key breast cancer updates in 2024. Dr Kalinsky is the director of the Glenn Family Breast Center at the Winship Cancer Institute of Emory University in Atlanta, Georgia, where he is also the Louisa and Rand Glenn Family Chair in Breast Cancer Research. At the Emory University School of Medicine, Dr Kalinsky is a professor, director of the Division of Medical Oncology, and, and director of Breast Medical Oncology in the Department of Hematology and Medical Oncology. 

In our exclusive interview, Dr Kalinsky discussed his top takeaways from the 2024 ASCO Annual Meeting and 2024 ESMO Congress, as well as where he sees the field of breast cancer headed in the future.

, supported by AstraZeneca. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

Kevin Kalinsky, MD, MS, discusses his top takeaways from the 2024 ASCO Annual Meeting and 2024 ESMO Congress, as well as where he sees the field of breast cancer evolving into the future. 

Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS

, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, talks through key updates in genitourinary cancer research from the 

In this episode, Dr Park highlights potentially practice-changing data in prostate, kidney, and bladder cancer; spotlights the potential clinical implications of findings with the intravesical therapy TAR-200 in patients with muscle-invasive bladder cancer (MIBC); and zooms in on data from the phase 3 NIAGARA trial (NCT03732677) of durvalumab (Imfinzi) plus gemcitabine and cisplatin in patients with MIBC.

Chandler Park, MD, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress.

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

In today’s episode, supported by Coherus Biosciences, we had the pleasure of speaking with Tarek Mekhail, MD, MSC, FRCSI, FRCSEd, about the use of toripalimab-tpzi (Loqtorz) in patients with nasopharyngeal carcinoma. Dr Mekhail is the medical director of the Thoracic Cancer Program and the Associate Executive Director at the AdventHealth Cancer Institute in Orlando, Florida. 

In our exclusive interview, Dr Mekhail discussed the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma, clinical successes with toripalimab in the first- and second-line nasopharyngeal carcinoma settings, and what the future looks like regarding immunotherapy in this disease.

, supported by Coherus Biosciences. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

Dr Mekhail discusses the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma.

How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd

In today’s episode, supported by Taiho Pharmaceutical, we had the pleasure of speaking with Joleen Hubbard, MD, about practice-changing updates to the colorectal cancer (CRC) treatment paradigm. Dr Hubbard is a medical oncologist at Allina Health Cancer Institute in Minneapolis, Minnesota.

In our exclusive interview, Dr Hubbard discussed key efficacy and safety findings from the phase 3 SUNLIGHT trial (NCT04737187) of trifluridine-tipiracil (Lonsurf) plus bevacizumab (Avastin) in patients with refractory metastatic CRC; quality of life outcomes from this trial; and the most practice-changing updates to the National Comprehensive Cancer Network guidelines for CRC.

, supported by Taiho Pharmaceutical. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

Dr Hubbard discusses efficacy, safety, and quality of life outcomes from the SUNLIGHT trial of trifluridine-tipiracil plus bevacizumab in metastatic CRC.

SUNLIGHT QOL Data Show Positive Outcomes With Trifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD

 series, Chandler Park, MD, a genitourinary medical oncologist at Norton Cancer Institute in Louisville, Kentucky, hosted a conversation with Vivek Subbiah, MD, a medical oncologist and chief of Early-Phase Drug Development at Sarah Cannon Research Institute in Nashville, Tennessee. Dr Subbiah, an internationally recognized expert, discussed advancements in precision oncology, emphasizing the effects of next-generation sequencing and tissue-agnostic therapies on personalized cancer treatment.

Dr Subbiah highlighted the transformation in genome sequencing that has taken place since the Human Genome Project, noting the reduction in sequencing costs from $3.3 billion to potentially $1 per genome. He explained how this evolution supports the expansion of precision oncology by making genomic testing accessible across diverse health care settings. Another key focus was on the evolving landscape of tissue-agnostic therapies, a novel approach that targets cancers based on shared molecular markers rather than the tumor’s origin. Dr Subbiah detailed the timeline of the FDA's tissue-agnostic drug approvals, beginning with pembrolizumab (Keytruda) for microsatellite instability–high or mismatch repair–deficient cancers, followed by inhibitors of 

The conversation concluded with Dr Subbiah’s vision for the future of precision oncology, where comprehensive molecular profiling, including proteomics and metabolomics, will become routine. He called for faster drug development and greater integration of genomic testing in standard care, predicting that by 2050, precision medicine will encompass numerous tissue-agnostic therapies, enabling highly personalized and effective treatments across all patient demographics.

In this Oncology Unplugged episode, Dr. Chandler Park and Dr. Vivek Subbiah discuss advancements in precision oncology, next-gen sequencing, and tissue-agnostic therapies.

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD  

that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays. 

Podcasts

All Podcast Series

How This Is Building Me

Two Onc Docs

Blood Club

FDA Approval Insights

Oncology Expert Insights

OncClub

Conference Perspectives

Women In Oncology

Rare Cancers

Disparities

Fellowship

Roundtable Discussions

Latest Conference Coverage